Viridian Therapeutics' Veligrotug Shows Durable Proptosis Response in Phase 3 TED Trial

Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the best low priced pharma stocks to buy now. Earlier on May 20, Viridian Therapeutics announced positive long-term durability data from its Phase 3 THRIVE clinical trial of veligrotug (“veli”). Veligrotug is an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody being developed for active thyroid eye disease/TED, which is an autoimmune condition that causes inflammation, growth, and damage to tissues around and behind the eye.

The THRIVE Phase 3 clinical trial in active TED evaluated 5 infusions of veligrotug or placebo administered every 3 weeks, with the primary topline analysis conducted at week 15, and patients followed through week 52. The new data reveal strong durability: 70% (21 out of 30) of veligrotug-treated patients in THRIVE who were proptosis responders at week 15 and continued follow-up to week 52, maintained their proptosis response.

The safety profile remained consistent during the follow-up period, with the vast majority of adverse events reported at the week 15 primary analysis having resolved by week 52. Veligrotug recently received Breakthrough Therapy Designation/BTD from the FDA, which supports its eligibility for Priority Review.

Viridian Therapeutics Inc. (NASDAQ:VRDN) discovers, develops, and commercializes treatments for serious and rare diseases.

While we acknowledge the potential of VRDN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.